442 related articles for article (PubMed ID: 26706012)
21. Multiple unilateral schwannomas: segmental neurofibromatosis type 2 or schwannomatosis?
Leverkus M; Kluwe L; Röll EM; Becker G; Bröcker EB; Mautner VF; Hamm H
Br J Dermatol; 2003 Apr; 148(4):804-9. PubMed ID: 12752143
[TBL] [Abstract][Full Text] [Related]
22. Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.
Castellanos E; Bielsa I; Carrato C; Rosas I; Solanes A; Hostalot C; Amilibia E; Prades J; Roca-Ribas F; Lázaro C; Blanco I; Serra E;
BMC Med Genomics; 2015 Jan; 8():2. PubMed ID: 25739810
[TBL] [Abstract][Full Text] [Related]
23. [Neurofibromatosis type 2].
Goutagny S; Bouccara D; Bozorg-Grayeli A; Sterkers O; Kalamarides M
Rev Neurol (Paris); 2007 Sep; 163(8-9):765-77. PubMed ID: 17878803
[TBL] [Abstract][Full Text] [Related]
24. Astrocytic hamartoma of the optic disc and multiple café-au-lait macules in a child with neurofibromatosis type 2.
Sachdeva R; Rothner DA; Traboulsi EI; Hayden BC; Rychwalski PJ
Ophthalmic Genet; 2010 Dec; 31(4):209-14. PubMed ID: 21067482
[TBL] [Abstract][Full Text] [Related]
25. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors.
Louis DN; Ramesh V; Gusella JF
Brain Pathol; 1995 Apr; 5(2):163-72. PubMed ID: 7670657
[TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
Miyakawa T; Kamada N; Kobayashi T; Hirano K; Fujii K; Sasahara Y; Nagai Y; Shinkai H
J Dermatol; 2007 Jan; 34(1):60-4. PubMed ID: 17204104
[TBL] [Abstract][Full Text] [Related]
27. Neurofibromatosis type 2.
Evans GR; Lloyd SKW; Ramsden RT
Adv Otorhinolaryngol; 2011; 70():91-98. PubMed ID: 21358190
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II].
Evans DG
Genet Med; 2009 Sep; 11(9):599-610. PubMed ID: 19652604
[TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis type 2.
Slattery WH
Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
[TBL] [Abstract][Full Text] [Related]
30. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
Aghi M; Kluwe L; Webster MT; Jacoby LB; Barker FG; Ojemann RG; Mautner VF; MacCollin M
J Neurosurg; 2006 Feb; 104(2):201-7. PubMed ID: 16509493
[TBL] [Abstract][Full Text] [Related]
31. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
33. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract][Full Text] [Related]
34. [Pathogenesis and molecular pathology of vestibular schwannoma].
Brodhun M; Stahn V; Harder A
HNO; 2017 May; 65(5):362-372. PubMed ID: 27421984
[TBL] [Abstract][Full Text] [Related]
35. [Type 2 neurofibromatosis: intergenerational differences in genetic and clinical expression].
Drouet A; Le Moigne F; Salamé D; Quesnel L; Motolese C; des Portes V; Guilloton L; Pinson S
Arch Pediatr; 2014 Nov; 21(11):1233-40. PubMed ID: 25439059
[TBL] [Abstract][Full Text] [Related]
36. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
Cumpston EC; Rhodes SD; Yates CW
Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
[TBL] [Abstract][Full Text] [Related]
37. Multiple Meningiomas as a Criterion for the Diagnosis of Neurofibromatosis Type 2 and Other Tumor Predisposition Syndromes.
Hannan CJ; Hammerbeck-Ward C; Pathmanaban ON; Smith MJ; Rutherford SA; Lloyd SK; Mackenzie Freeman SR; Wallace AJ; King AT; Richard Evans DG
Neurosurgery; 2022 Jun; 90(6):793-799. PubMed ID: 35343466
[TBL] [Abstract][Full Text] [Related]
38. Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas.
Hadfield KD; Smith MJ; Urquhart JE; Wallace AJ; Bowers NL; King AT; Rutherford SA; Trump D; Newman WG; Evans DG
Oncogene; 2010 Nov; 29(47):6216-21. PubMed ID: 20729918
[TBL] [Abstract][Full Text] [Related]
39. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
40. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
